Michael Buckner/Getty Images Entertainment

The board at Activision Blizzard (NASDAQ:ATVI) pushed back Thursday against the drumbeat of media stories about accusations of harassment in company culture.

In a long letter it included in an SEC filing, the board said that it had promised to dig into issues directly, and “What we have come to realize over the past several months is that there are many truths about our company – individual and collective, experiential and data-driven – and sometimes they can be difficult to reconcile.”

Media criticism of the board and senior executives as insensitive to workplace matters, though is “without merit. Activision Blizzard senior executives responded in a timely manner and with integrity and resolve to improve the workplace.”

“Contrary to many of the allegations, the Board and its external advisors have determined that there is no evidence to suggest that Activision Blizzard senior executives ever intentionally ignored or attempted to downplay the instances of gender harassment that occurred and were reported,” the letter read.

While it notes “a single instance of someone feeling diminished at Activision Blizzard is one too many,” the board says there isn’t a systemic problem with harassment, discrimination or retaliation at the company, and that “based on the volume of reports, the amount of misconduct reflected is comparatively low for a company the size of Activision Blizzard.”

Their work also hasn’t unearthed any evidence suggesting any attempt by a senior executive or employee to conceal information from the board, it said.

Notably, that’s pushback on November reports that CEO Bobby Kotick knew for years about sexual-misconduct allegations and that he kept some reports from the board.

Read More

RiverNorthPhotography/iStock via Getty Images

The Federal Trade Commission (FTC) voted unanimously to adopt a policy statement on Thursday stating its intention to more closely examine the rebates and fees paid by drug manufacturers to Pharmacy Benefit Managers (PBMs) to get preferred coverage for their drugs from payers.

The five-member commission, including two Republican commissioners, voted 5-0 to increase the scrutiny of the practice to assess its impact on payers and patients.

“These rebate and fee agreements may incentivize PBMs and other intermediaries to steer patients to higher-cost drugs over less expensive alternatives,” the FTC wrote.

Acting as middlemen between drugmakers and consumers, PBMs decide which drugs get covered by health insurance plans and negotiate prices with manufacturers.

Leading PBMs include the Caremark unit of CVS Health Corporation (NYSE:CVS), Express Scripts of Cigna (CI), and OptumRx of UnitedHealth Group (UNH).

The commission has paid particular attention to insulin to highlight the impact of the arrangement. Citing research, FTC points out that the wholesale price of the lifesaving medication has nearly tripled between 2009 and 2017, raising out-of-pocket costs for both insured and uninsured patients.

Notable insulin manufacturers include Eli Lilly (LLY), Sanofi (SNY), and Novo Nordisk (NVO).

Last week, the FTC said it would launch an investigation into how vertically integrated pharmacy benefit managers affect the price and availability of prescription drugs.

Under the probe, companies including CVS Health (CVS), Cigna (CI) and UnitedHealth (UNH), and Humana (HUM) were expected to receive subpoenas for information.

Read More

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Read More